Target intelligence / Profile preview

Sendai virus fusion protein at the hemagglutinin-neuraminidase interface (SeV F-HN interface)

Target
SeV F-HN interface
Molecular classification
Viral glycoprotein, Type I membrane protein, Class I viral fusion protein, Protein-protein interface
01

Overview

The Sendai virus fusion (F) protein at the hemagglutinin-neuraminidase (HN) interface is a critical structural site for the entry of the Sendai virus (SeV), a member of the Paramyxoviridae family, into host cells. The F protein is a class I viral fusion protein that mediates the merging of the viral envelope with the host cell membrane, a process that is triggered by the binding of the HN protein to sialic acid receptors on the cell surface. The physical interaction between the HN and F proteins at this specific interface is essential for transmitting the triggering signal that induces the F protein to undergo a massive irreversible conformational change from a metastable pre-fusion state to a stable post-fusion state. Because this interaction is a prerequisite for viral infectivity, the HN-F interface represents a high-value target for the development of antiviral therapeutics. Small molecules or peptides designed to bind at this interface can effectively block the triggering mechanism, thereby preventing viral entry and subsequent respiratory infection. Understanding the precise molecular architecture of this interface is vital for designing broad-spectrum inhibitors against related human pathogens, such as human parainfluenza viruses.

Other names
SeV F proteinSendai virus F-HN complexMurine respirovirus fusion proteinParamyxovirus fusion protein interface
02

Mechanism of action

Inhibition of the conformational transition of the fusion protein from a pre-fusion to a post-fusion state by blocking the essential interaction with the hemagglutinin-neuraminidase protein.

03

Biological functions

Viral entryMembrane fusionViral attachmentHost cell penetration
04

Disease associations

InfectionRespiratory tract infectionPneumoniaBronchiolitis
05

Safety considerations

Viral resistance through mutations at the interfacePotential for cross-reactivity with other paramyxovirusesDelivery challenges for peptide-based inhibitors
06

Interacting drugs

Peptide inhibitors (e.g., HR2-derived peptides)

1 more in the full profile.

07

Biomarkers

Viral load (SeV RNA)F protein expression levelsNeutralizing antibody titers

Beyond the preview

Go deeper on Sendai virus fusion protein at the hemagglutinin-neuraminidase interface (SeV F-HN interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sendai virus fusion protein at the hemagglutinin-neuraminidase interface (SeV F-HN interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call